Patents by Inventor Kevin J. Stefanski

Kevin J. Stefanski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS
    Publication number: 20220144835
    Abstract: This invention relates to solid amorphous Compound (I) having the formula (I) and to solid amorphous dispersions comprising Compound (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability. This invention relates to solid amorphous dispersions comprising Compound (I) having the formula (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability.
    Type: Application
    Filed: April 10, 2020
    Publication date: May 12, 2022
    Inventors: Robert J. GARMISE, Jaquan Kalani LEVONS, Jay Poorna REDDY, Kevin J. STEFANSKI, Vrushali M. WAKNIS, Theresa M. ZIEMBA, Ajay SAXENA, Srikanth Koravady SRIDHAR, Gajendra Singh CHOWAN, Sharmistha PAL, Shabeerali PATTASSERI, Roopa NARASIMHAMURTHY, Narayan Swamy PANDURANGA
  • Bioavailable compositions of amorphous piperidinyl compounds
    Patent number: 9095585
    Abstract: This invention relates to solid amorphous dispersions comprising Compound I having the formula (formula I), or stereoisomers thereof, and one or more polymers. More particularly, this invention relates to bioavailable amorphous solid dispersions of Compound I that are unexpectedly stable in suspension and in the solid state for extended periods of time that may be used for tabletting.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: August 4, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rodney D. Vickery, Kevin J. Stefanski, Ching-Chiang Su, Michael J. Hageman, Balvinder S. Vig, Seema Betigeri
  • BIOAVAILABLE COMPOSITIONS OF AMORPHOUS PIPERIDINYL COMPOUNDS
    Publication number: 20140163071
    Abstract: This invention relates to solid amorphous dispersions comprising Compound I having the formula (formula I), or stereoisomers thereof, and one or more polymers. More particularly, this invention relates to bioavailable amorphous solid dispersions of Compound I that are unexpectedly stable in suspension and in the solid state for extended periods of time that may be used for tabletting.
    Type: Application
    Filed: July 20, 2012
    Publication date: June 12, 2014
    Inventors: Rodney D. Vickery, Kevin J. Stefanski, Ching-Chiang Su, Michael J. Hageman, Balvinder S. Vig, Seema Betigeri
  • Solid-state form of celecoxib having enhanced bioavailability
    Patent number: 7220867
    Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 22, 2007
    Assignee: Pharmacia Corporation (of Pfizer, Inc.)
    Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. MacKin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
  • Solid-state form of celecoxib having enhanced bioavailability
    Patent number: 6964978
    Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: November 15, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. Mackin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
  • Pharmaceutical composition having reduced tendency for drug crystallization
    Publication number: 20030045563
    Abstract: An orally deliverable pharmaceutical composition is provided comprising a drug of low water solubility, a solvent liquid that comprises at least one pharmaceutically acceptable solvent, and a turbidity-decreasing polymer, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the polymer is present in an amount sufficient to substantially inhibit crystallization and/or precipitation of the drug in simulated gastric fluid.
    Type: Application
    Filed: January 15, 2002
    Publication date: March 6, 2003
    Inventors: Ping Gao, Michael J. Hageman, Walter Morozowich, Robert J. Dalga, Kevin J. Stefanski, Tiehua Huang, Aziz Karim, Fred Hassan, James C. Forbes
  • Solid-state form of celecoxib having enhanced bioavailability
    Publication number: 20020006951
    Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Application
    Filed: December 6, 2000
    Publication date: January 17, 2002
    Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. Mackin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski